Palvella Therapeutics (PVLA) announced the appointment of Ashley Kline as Chief Commercial Officer, effective immediately. Prior to joining Palvella as Chief Commercial Officer, she served as Global Biotech Head and U.S. General Manager at Dompe Pharmaceuticals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Promising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market Position
- Palvella Therapeutics price target lowered to $52 from $53 at Canaccord
- Promising Outlook for Palvella Therapeutics: Buy Rating Backed by Strong Financials and Innovative QTORIN Platform
- Palvella Therapeutics Reports Strong Q1 Financial Results
- Palvella Therapeutics reports Q1 EPS (74c), consensus ($1.32)